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The rate of detection of thyroid nodules and carcinomas has increased with the widespread use of ultrasonography (US), 
which is the mainstay for the detection and risk stratification of thyroid nodules as well as for providing guidance for their 
biopsy and nonsurgical treatment. The Korean Society of Thyroid Radiology (KSThR) published their first recommendations 
for the US-based diagnosis and management of thyroid nodules in 2011. These recommendations have been used as the 
standard guidelines for the past several years in Korea. Lately, the application of US has been further emphasized for the 
personalized management of patients with thyroid nodules. The Task Force on Thyroid Nodules of the KSThR has revised the 
recommendations for the ultrasound diagnosis and imaging-based management of thyroid nodules. The review and recommendations 
in this report have been based on a comprehensive analysis of the current literature and the consensus of experts.
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INTRODUCTION
The management of thyroid nodules has become a 
controversial issue with the increasing incidence of thyroid 
carcinomas. The prevalence of thyroid nodules is 2–6% 
with palpation, 19–68% with ultrasonography (US), and 
8–65% in autopsy specimens (1-3). The rate of malignancy 
was approximately 5–15% among the nodules detected by 
palpation or US (3-5). The rate of malignancy was 8–12% 
of the nonpalpable nodules evaluated by fine-needle 
aspiration (FNA) (4, 5), and 1.6% among the patients 
with thyroid nodules in a population-based study (6). 
The rate of detection of thyroid carcinoma has increased 
lately with the widespread use of US for its diagnosis 
(7). Micropapillary thyroid carcinoma is the leading cause 
for the recent increase in incidence of thyroid cancer in 
South Korea and the United States (8, 9). Lately, the role 
of US has been further emphasized for the personalized 
management of patients with thyroid nodules. First, the 
selection of patients for FNA of a thyroid nodule is primarily 
determined by the assessment of the US findings in most 
of the patients with asymptomatic thyroid nodules. Second, 
the management procedure of a thyroid nodule is mainly 
determined by the cancer probability and the prognostic risk 
factors estimated by US. Third, the US assessment is crucial 
for the preoperative evaluation as well as the postoperative 
surveillance in thyroid cancer. Fourth, the image-guided 
ablation methods such as chemical or thermal ablations are 
being increasingly used in the treatment of benign thyroid 
nodules (10).
The Korean Society of Thyroid Radiology (KSThR) had 
published consensus recommendations for the US-based 
management of thyroid nodules in 2011 (11). Recent 
many advances in the diagnosis and nonsurgical therapy 
of thyroid nodules have necessitated the revision of the 
original recommendations. The KSThR therefore organized 
a taskforce for the revision of the recommendations 
from September 2014 (Supplementary Tables 1-3 in the 
online-only Data Supplement). The major update of the 
revised KSThR recommendations includes the revised US 
malignancy risk stratification system for thyroid nodules, 
i.e., the Korean Thyroid Imaging Reporting and Data System 
(K-TIRADS), risk stratification of cervical lymph nodes 
(LN) on the basis of the US and computed tomography 
(CT) features, and recommendations for the image-guided 
ablation of benign thyroid nodules. A PubMed MEDLINE 
search was performed for retrieving publications from 1990 
to October 2015 with the following keywords: thyroid 
nodule, thyroid carcinoma, cervical LN, US, CT, and ablation. 
Since clinical controversies over the issues exist in many 
of the areas, the recommendations regarding some of the 
issues are based on expert opinion. This limitation needs 
to be overcome in the near future when new evidences 
are accumulated. The goal of these recommendations is 
to provide the best scientific evidence available and a 
consensus expert-opinion regarding the US-based diagnosis 
and management of thyroid nodules in clinical practice.
Terminology and US Features in Thyroid Nodule
The US terminology of thyroid nodules should have 
feasibility for clinical application, utility for malignancy 
risk stratification, and low interobserver variability. The 
recommended terminology and definition of the US features 
are summarized in Table 1.
The Nodule Size
The size of a thyroid nodule should be measured in all 
three dimensions; however, only the maximal diameter 
of the nodule may be documented in small nodules (≤ 5 
mm). The correlation between the nodule size and the risk 
for malignancy remains controversial. Although a recent 
systemic review suggested that the larger nodules present a 
higher pretest probability of malignancy (12), whether the 
malignancy risk is higher in the larger nodules and whether 
the nodule size could be a predictor for malignancy are 
still controversial (13-15). The growth of a nodule is not a 
reliable predictor of malignancy since many benign nodules 
can slowly grow over time (16-19). However, the rapid 
growth of a solid nodule can be a clinical manifestation 
of a high grade malignancy such as anaplastic thyroid 
carcinoma or lymphoma. The accurate estimation of the 
nodule growth is essential for deciding the management 
strategy for the follow-up of suspected or proven papillary 
thyroid microcarcinomas. It is also required for the follow-
up management of the nodules with an indeterminate 
or benign cytology diagnosis. For the estimation of a 
significant size change of a nodule, we recommend defining 
a significant size change as the nodule growth with a 20% 
increase in at least two nodule dimensions and a minimal 
increase of 2 mm, or more than a 50% change in volume (20). 
Internal Content 
The internal content of a nodule is categorized in terms 
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of the ratio of the cystic portion to the solid portion in the 
nodule: solid (no obvious cystic content), predominantly 
solid (≤ 50% of the cystic portion), predominantly cystic 
(> 50% of the cystic portion), and cystic (no obvious solid 
content) (Supplementary Fig. 1 in the online-only Data 
Supplement). We recommend that the nodules with minimal 
cystic changes (< 10%) be categorized as predominantly 
solid nodules because their malignancy risk seems to be 
similar to that of the partially cystic (predominantly solid or 
predominantly cystic) nodules (21). Most of the malignant 
thyroid tumors are solid (81.6–93%) (22-25), and the 
malignancy risk of the solid nodules is higher (24.1–34.7%) 
than that of the partially cystic nodules (3.3–7.1%) (22, 
24-26). 
We suggest that the spongiform appearance of a nodule 
be defined as the aggregation of multiple microcystic 
Table 1. Recommended US Terminology and Definition for Thyroid Nodules
US Characteristics Category Definition Synonym
Internal content 
  (composition)
Solid No obvious cystic component
Predominantly solid Cystic portion ≤ 50%
Predominantly cystic Cystic portion > 50%
Cystic No solid portion Pure cyst
Echogenicity
Marked hypoechogenicity Hypoechoic relative to adjacent anterior neck muscle
Mild hypoechogenicity Hypoechoic relative to thyroid parenchyma
Isoechogenicity Same echogenicity as that of thyroid parenchyma
Hyperechogenicity Hyperechoic relative to thyroid parenchyma
Shape
Round to oval Round or oval regardless of orientation 
Irregular Neither round nor oval 
Orientation
Parallel
Anteroposterior diameter shorter or equal to 
  transverse or longitudinal diameter 
Nonparallel 
Anteroposterior diameter longer than transverse 
  or longitudinal diameter on transverse or 
  longitudinal image
Taller-than-wide 
  shape 
Margin
Smooth Obviously discernible smooth edge
Regular, 
  circumscribed
Spiculated/microlobulated 
Obviously discernible, but non-smooth edge showing 
  spiculation, microlobulation, or jagged appearance
Irregular, infiltrative, 
  non-smooth 
Ill-defined
Poorly demarcated margin which cannot be obviously 
  differentiated from adjacent thyroid tissue
Indistinct
Calcification
Microcalcification 
Echogenic foci of 1 mm or less with or without 
  posterior acoustic shadowing within solid portion
Macrocalcification 
Echogenic foci larger than 1 mm with posterior 
  acoustic shadowing 
Coarse calcification
Rim calcification 
Peripheral curvilinear echogenic rim (complete or 
  incomplete) 
Egg shell calcification
Halo Present or absent Thin or thick hypoechoic rim surrounding nodule 
Spongiform Present or absent
Isoechoic nodule with microcystic change greater 
  than 50% of nodule
Honeycomb
Colloid 
  (comet-tail artifact)
Present or absent
Echogenic foci with reverberation artifacts within 
  cystic component
Vascularity
Type 1 (none) Absence of intranodular or perinodular vascularity
Type 2 (perinodular 
  vascularity)
Presence of circumferential vascularity at margin 
  of nodule
Type 3 (mild intranodular 
  vascularity)
Intranodular vascularity with or without perinodular 
  vascularity (lesser than 50%) 
Type 4 (marked intranodular 
  vascularity)
Marked intranodular vascularity with or without 
  perinodular vascularity (greater than 50%)
US = ultrasonography
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components in more than 50% of the isoechoic partially 
cystic nodule (Supplementary Fig. 2 in the online-only 
Data Supplement). An isoechoic spongiform nodule can 
be regarded as a benign nodule with a malignancy risk 
less than 1% (27-30). Spongiform appearance is rarely 
found in papillary carcinomas (30, 31), and the presence 
of hypoechogenicity or microcalcification may increase the 
malignancy risk in the nodules with sponge-like areas (30). 
Echogenicity
We suggest that the nodule echogenicity be categorized 
on the basis of the relative echogenicity compared to the 
reference structures (thyroid parenchyma and anterior 
neck muscles). Nodule echogenicity is categorized as 
being markedly hypoechoic (hypoechoic relative to the 
anterior neck muscle), mildly hypoechoic (hypoechoic 
relative to the thyroid parenchyma, but not hypoechoic 
relative to the anterior neck muscles), isoechoic (same 
echogenicity as that of the thyroid parenchyma), or 
hyperechoic (more echogenic relative to the thyroid 
parenchyma) (Supplementary Fig. 3 in the online-only Data 
Supplement). When the echogenicity of a solid component 
is heterogeneous or mixed, the echogenicity of a nodule 
is defined by the predominant echogenicity. When the 
thyroid parenchyma shows abnormal hypoechogenicity in 
the case of thyroiditis, the nodule echogenicity should still 
be described relative to the same reference structures and 
the abnormal thyroid echogenicity should be described. A 
majority of the malignant thyroid tumors are hypoechoic 
(mild or marked) (62.5–87.2%), and the malignancy risk 
of the hypoechoic nodules is higher (20.6–70.4%) than 
that of the isoechoic (8.6–13.4%) or hyperechoic nodules 
(0–18.2%) (22, 24, 25, 27, 32). Although the markedly 
hypoechoic nodules are highly predictive of malignancy (27, 
33), the malignancy risk of the markedly hypoechoic solid 
nodules without the presence of any other suspicious US 
features was only intermediate, and not as high as that of 
the mildly or markedly hypoechoic solid nodules with other 
suspicious US features present (25). 
Nodule Shape and Orientation 
We suggest that the shape of a nodule be categorized 
as round to ovoid and irregular. The orientation of the 
direction of growth of a nodule is categorized as parallel 
(when the anteroposterior diameter of a nodule is equal to 
or less than its transverse or longitudinal diameter) or non-
parallel (when the anteroposterior diameter of a nodule 
is longer than its transverse or longitudinal diameter) on 
a transverse or longitudinal plane (Supplementary Fig. 4 
in the online-only Data Supplement). The orientation is 
categorized according to the relationship of the long axis of 
a nodule to the long axis of thyroid gland on imaging plane 
regardless of the nodule shape (oval to round or irregular). 
The nonparallel orientation presents the same US feature as 
the taller-than-wide shape defined previously (11, 33). This 
finding indicates that the malignant nodules grow across 
the normal tissue plane in a centrifugal manner, while 
benign nodules do the same in a parallel fashion (33-35). 
Although the nodules with round to ovoid shape or parallel 
orientation are more frequently found in benign nodules, 
the features are not specific for benign nodules, and are 
commonly found in follicular carcinomas or the follicular 
variant of papillary thyroid carcinoma (PTC) (36-38). A 
nodule with an irregular shape is not specific for benign or 
malignant nodules (27, 39, 40). The nonparallel orientation 
(taller-than-wide) feature is less sensitive, but highly 
specific for malignancy, with a specificity of 88.4–98.7% 
and a positive predictive value of 71.2–77.5% (24, 25, 27). 
Nodule Margin 
The US terminology for the nodule margin is controversial 
(11, 27, 41-44), and many different terminologies have been 
used to describe the margins of the malignant tumors. We 
suggest the margin of a nodule be categorized as smooth, 
spiculated/microlobulated, or ill-defined (Supplementary 
Fig. 5 in the online-only Data Supplement). An obviously 
discernible margin is categorized as either a smooth or a 
spiculated/microlobulated margin. When the margin of any 
portion of a nodule is obviously spiculated/microlobulated, 
it is categorized as a spiculated/microlobulated margin. A 
smooth margin is mostly found in the hypoechoic nodules, 
isoechoic nodules with hypoechoic halo, and nodules of 
heterogeneous composition. A spiculated or microlobulated 
margin is mostly found in the infiltrating malignant tumors, 
which are mostly found in the hypoechoic nodules and 
rarely in the isoechoic nodules with a partly hypoechoic 
portion or hypoechoic rim (Supplementary Fig. 6 in the 
online-only Data Supplement). While a smooth margin is 
not specific for benign or malignant nodules, a spiculated/
microlobulated margin is highly suggestive of a malignancy, 
with a specificity of 90.8–98.4% and a positive predictive 
value of 79.8–86.7% (25, 27, 39). Meanwhile, the margin of 
a nodule might be indistinct in the isoechoic nodules when 
the periphery of the nodule has similar echogenicity and 
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composition as the surrounding normal gland, as is typically 
found in the isoechoic hyperplastic nodules without 
encapsulation (40). An ill-defined margin is also found in 
some hypoechoic nodules, including focal thyroiditis (45, 
46) and infiltrative malignant tumors. 
A nodule sometimes shows an accompanying hypoechoic 
thin or thick halo. Histologically, the halo sign or 
hypoechoic rim surrounding a nodule is comprised of the 
nodule capsule or pseudocapsule, compressed thyroid 
tissue, and caused by chronic inflammatory changes (47-
50). Although the halo sign is more frequently found in the 
benign nodules, it is not highly specific for the benignity 
(40, 51) and frequently found in follicular neoplasm 
(36, 52), and the absence of the halo is less specific for 
malignancy (53, 54). 
Calcification, Echogenic Foci 
The calcifications are categorized as microcalcifications 
(punctuate echogenic foci of 1 mm or less either with 
or without posterior shadowing; brighter echo than the 
surrounding thyroid tissue), macrocalcifications (echogenic 
foci greater than 1 mm in size with posterior shadowing), 
and rim calcifications (peripheral curvilinear or eggshell 
calcification at the nodule margin) (Supplementary Fig. 
7 in the online-only Data Supplement). The punctuate 
echogenic foci found within the solid portion may be either 
true microcalcification or colloid material. Pathologically, 
a microcalcification is a psammoma body comprised of 
10–100 μm round, laminar, crystalline, calcified deposits, 
which is very specific for thyroid carcinoma and, especially, 
for PTC. The echogenic foci are sometimes accompanied by 
reverberation artifacts within the cystic portion–the so-
called comet-tail artifacts; these artifacts are caused by 
the colloid materials, and are almost always suggestive of 
benignity (55-57). We recommend that the US features of 
the comet-tail artifacts be used for diagnosis only when 
they are found within the cystic portion of a nodule, 
because the comet-tail artifacts within the solid portion are 
not reliably differentiated from the microcalcifications, and 
are not specific for a benign nodule (57). Large nodular or 
linear echogenic foci without posterior shadowing at the 
septa or the wall of the cystic nodules are mostly found 
in benign cystic nodules, and should not be considered as 
calcifications (56). 
Microcalcification has been reported to be highly 
suggestive of malignancy, with a reported specificity of 
84–97% and a positive predictive value of 33–78% (4, 
22, 24, 25, 27, 58). However, it should be noted that 
the malignancy risk of the microcalcifications is high in 
the solid hypoechoic nodules, but intermediate in the 
partially cystic or isohyperechoic nodules (25). Although 
the presence of macrocalcifications might increase 
the malignancy risk (27, 40), they are not specific for 
malignancies and present a variable malignancy risk (23.9–
64.8%) (25, 27, 59). Although the malignancy risk of the 
isolated macrocalcifications composed of entirely calcified 
nodules without any solid portions may be low (0–16%) 
(59, 60), a PTC with an aggressive behavior may rarely 
manifest as an isolated macrocalcification (60). An isolated 
macrocalcifcation may be considered as an intermediate 
suspicion nodule. However, there is not enough evidence. 
Although the rim or eggshell calcifications are not 
significantly associated with malignancy (22, 27, 40), 
the presence of a hypoechoic halo or a solid portion 
accompanying the disruption of the eggshell or rim 
calcifications may increase the malignancy risk (61, 62).
 
Nodule Vascularity 
Color Doppler or power Doppler US can be used for 
the evaluation of the vascularity of thyroid nodules. The 
vascularity patterns of thyroid nodules can be categorized 
as four types according to the patterns of the nodular 
vascularity: type 1, absence of nodule vascularity; type 2, 
perinodular vascularity only (presence of circumferential 
vascularity at the margin of a nodule); type 3, mild 
intranodular vascularity with or without perinodular 
vascularity (vascularity lesser than 50%); type 4, marked 
intranodular vascularity with or without perinodular 
vascularity (vascularity greater than 50%). The presence of 
intranodular vascularity is variably observed in 16.7–91.7% 
of the malignant tumors (4, 51, 63-67) and 30.7–65.3% 
of the benign nodules (63-67). Although the presence of 
intranodular vascularity might increase the risk of malignancy 
(4, 64), there are no consistent results regarding the 
association of an intranodular vascularity pattern with the 
risk of malignancy (63, 66-68). Recent studies reported that 
the presence of intranodular vascularity was not predictive 
of the malignancy (25, 67), and that it could not provide 
an added value over that of the gray-scale US alone for the 
prediction of the malignancies of the overall thyroid nodules 
(67). Additionally, higher resistive index (RI) or pulsatility 
index Doppler index values might be predictive of malignancy. 
However, the cutoff value of each of the indices and their 
complementary role in the diagnosis of malignancies has 
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not yet been established (68). Although the presence of a 
marked intranodular vascularity pattern might be predictive 
of malignancy in the follicular lesions or follicular neoplasm 
(69-73), the hypothesis remains controversial (74). 
US Elastography 
Ultrasonographic elastography is a new technique for 
the measurement of the elasticity of the tissues. The tissue 
of the carcinoma is usually harder and firmer than that of 
the normal thyroid parenchyma or a benign nodule. There 
are two representative elastography techniques to quantify 
the tissue strain. The first is “strain elastography”, which 
evaluates the degree of tissue deformation induced by 
compression or acoustic forces. The second method of 
elastography is the “shear wave” speed measurement, where 
the shear waves propagate in a direction orthogonal to 
the direction of the tissue displacement. The propagation 
speed is generally higher in the malignant thyroid nodules 
than in the benign ones (75, 76). Although several studies 
(77, 78) have reported that US elastography performed 
the same or better than the gray-scale US, the clinical 
efficiency or the complementary role of elastography in 
the diagnosis of thyroid nodules is still controversial (79). 
Recently, several studies (80-84) reported the potential role 
of US elastography in the diagnosis of thyroid nodules with 
indeterminate or non-diagnostic cytology as well as those 
with indeterminate US features. Further investigations 
are required for establishing the supplementary role of US 
elastography in the risk stratification of thyroid nodules.
US-Risk Stratification and the Korean Thyroid 
Imaging Reporting and Data System 
The US stratification of the malignancy risk has an 
essential role in deciding for or against FNA of thyroid 
nodules. Recent meta-analysis studies (53, 54, 85) have 
consistently demonstrated that the gray-scale US features 
of microcalcification, spiculated/microlobulated margins, 
and nonparallel orientation (taller-than-wide) are strongly 
predictive of malignancy, with a high specificity (greater 
than 80%) and a high positive likelihood ratio (greater 
than 3); the US features of the solid internal content and 
hypoechogenicity have also been shown to be predictive of 
malignancy, with an intermediate specificity and a modest 
likelihood ratio for the thyroid malignancies. Although 
these US features are independent predictors of malignancy, 
any single US predictor does not have both high sensitivity 
and high specificity for the detection of malignancies (24, 
25, 53, 54, 85). Since the malignancy risk estimated by 
US is not determined by a single US predictor, it should 
be assessed by a combination of the US features. The US-
malignancy risk stratification system of the thyroid nodules, 
TIRADS, was initially proposed by Horvath et al. (86). It 
has been investigated for its ability for the quantitative 
estimation of the malignancy risk using scoring systems 
based on the categorization of the US patterns (25, 86, 87) 
or based on the calculation of the number of suspicious 
US features and US risk scores (24, 39, 88). Previous 
reports suggest that the malignancy risk or the US features 
predicting the malignancy might differ according to the 
solidity (26, 89-91) and echogenicity (40) of the thyroid 
nodules. Most thyroid society guidelines (20, 92-95) suggest 
risk stratification systems based on the categorization of 
the US patterns for thyroid nodules. However, there has 
been no standardized malignancy risk stratification system 
for thyroid nodules.
A recent retrospective multicenter study (25) 
demonstrated that the predictability of the suspicious 
US features demonstrated a heterogeneous dependency 
on the solidity and echogenicity of the thyroid nodules. 
The presence of any suspicious US features in the solid 
hypoechoic nodules revealed a high malignancy risk (79%), 
and that in the partially cystic or isohyperechoic nodules 
revealed an intermediate risk (25%). We recommend a 
simplified clinically feasible K-TIRADS for the malignancy 
risk stratification of thyroid nodules (Fig. 1) (25). Thyroid 
nodules are categorized as high suspicion, intermediate 
suspicion, low suspicion, and benign nodules based 
on their malignancy risks stratified by the US patterns 
composed of the integrated solidity, echogenicity, and 
suspicious US features (Table 2, Figs. 2-5). Although the 
color Doppler US features of the intranodular vascularity 
and the elastography findings are potentially useful in the 
differentiation of the benign and malignant nodules, further 
studies are required to establish their complementary role 
in the risk stratification of thyroid nodules.
 
US Assessment of Extrathyroidal Tumor Extension
Extrathyroidal extension (ETE) of the primary tumor occurs 
in 11.5–30% of the differentiated thyroid carcinomas, and 
it increases the risk of recurrence and mortality (96, 97). 
The ETE can be minimal (pT3) or extensive (massive; pT4a), 
and the two types of ETE vary in their recurrence rates and 
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disease-free survival odds (97, 98). The clinical outcome 
is worse in the patients with a gross ETE than in those 
with a microscopic local invasion (99). Microscopic ETE is 
considered to be an intermediate risk factor, and gross ETE, 
a high risk factor for differentiated thyroid cancers; this 
difference can affect the treatment decision of surgery and 
RI therapy (20). 
The US assessment of the ETE shows a wide range 
of diagnostic sensitivities (15.0–88.9%), specificities 
(27.2–97.6%), and accuracy values (56.0–84.8%) for 
Fig. 1. Algorithm of K-TIRADS for malignancy risk stratification based on solidity and echogenicity of thyroid nodules. Modified 
from Na et al. Thyroid 2016;26:562-572 (25). *Microcalcification, nonparallel orientation, spiculated/microlobulated margin. K-TIRADS = Korean 
Thyroid Imaging Reporting and Data System, US = ultrasonography
High  
suspicion
(K-TIRADS 5)
Any suspicious
US features*
Solid
hypoechoic
Yes YesNo No
Any suspicious
US features*
Partially cystic
Thyroid nodule
Isohyperechoic
Intermediate
suspicion
(K-TIRADS 4)
Low
suspicion
(K-TIRADS 3)
Benign
(K-TIRADS 2)
- Pure cyst
-  Partially cystic with  
comet tail artifact
- Spongiform
Table 2. Malignancy Risk Stratification According to Korean Thyroid Imaging Reporting and Data System (K-TIRADS) and FNA 
Indications
Category US Feature
Malignancy 
Risk (%)
Calculated Malignancy 
Risk (%),  
Overall (LV, HV)
Calculated Sensitivity 
for Malignancy (%), 
Overall (LV, HV)
FNA§
5 High suspicion
Solid hypoechoic nodule with any 
  of 3 suspicious US features*
> 60 79.3 (60.9, 84.9) 51.3 (35.9, 56.7)
≥ 1 cm 
(> 0.5 cm, 
selective)
4
Intermediate 
  suspicion
1) Solid hypoechoic nodule without  
    any of 3 suspicious US features* or  
2) Partially cystic or isohyperechoic  
    nodule with any of 3 suspicious US  
    features*
15–50 25.4 (15, 33.6) 29.5 (29.9, 29.4) ≥ 1 cm
3 Low suspicion
Partially cystic or isohyperechoic  
  nodule without any of 3 suspicious  
  US features*
3–15 7.8 (6, 10.3)† 19.2 (34.2, 13.9) ≥ 1.5 cm
2 Benign‡
1) Spongiform < 3 0 0 ≥ 2 cm
2) Partially cystic nodule with comet  
    tail artifact
3) Pure cyst 
< 1 0 0 NA
1 No nodule - - - - NA
LV and HV indicate low and high cancer volume data, respectively. Solid hypoechoic nodules include solid nodules with marked or mild 
hypoechogenicity. *Microcalcification, nonparallel orientation (taller-than-wide), spiculated/microlobulated margin, †Malignancy risk 
calculated from nodules excluding spongiform or partially cystic nodules with comet tail artifacts, ‡K-TIRADS 2 (benign category) includes 
partially cystic nodules with spongiform appearance or comet tail artifacts which do not have any suspicious US feature, §FNA is indicated 
regardless of size and US feature of nodule in presence of poor prognostic factors including suspected lymph node metastasis by US or 
clinical evaluation, suspected extrathyroidal tumor extension, patients with diagnosed distant metastasis from thyroid cancer. Modified 
from Na et al. Thyroid 2016;26:562-572 (25). FNA = fine-needle aspiration, NA = not applicable for FNA, US = ultrasonography
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the diagnosis of the ETE (100-106). Although, the direct 
tumor invasion of the muscles or other organs around the 
thyroid gland is the hallmark of the gross ETE, the US-based 
diagnostic criteria for ETE is somewhat subjective and has 
not been established yet. The US features predictive of 
the ETE can be categorized as the presence of the capsular 
protrusion, disruption, and abutment (Supplementary Fig. 
8 in the online-only Data Supplement). Capsular protrusion 
is defined as the bulging into the adjacent structures 
with the loss of the normal tissue boundaries (102). The 
disruption of the capsular margin is defined as loss of the 
perithyroidal echogenic line at the site of contact with the 
thyroid cancer (100, 101). Capsular abutment is defined as 
the lack of intervening tissue between the thyroid cancer 
and the thyroid capsule (100), which can be graded by the 
perimeter ratio (abutment perimeter/nodule perimeter x 
100%) (101, 103) or the diameter ratio (abutting diameter/
whole tumor diameter x 100%) (104). If the perimeter 
ratio is greater than 25%, the possibility of ETE should be 
considered. The US-based diagnostic criteria for ETE remains 
debatable, and further, well-organized, prospective studies 
are required to determine the diagnostic accuracy of the US 
criteria for ETE. According to a recent study (107) of the 
low-risk papillary thyroid microcarcinomas, tracheal tumor 
invasion was found only in the subcapsular tumors attached 
to the trachea at the right or obtuse angles, and the tumor 
invasion of the recurrent laryngeal nerve was found only in 
the subcapsular tumors with the loss of intervening normal 
parenchyma in the direction of the recurrent laryngeal 
nerve (Supplementary Figs. 8, 9 in the online-only Data 
Supplement). 
Indications for US-Guided Fine-Needle 
Aspiration
Fine-needle aspiration has been established as a safe, 
A
C
B
D
Fig. 2. Korean Thyroid Imaging Reporting and Data System 5 (high suspicion). 
A. Solid hypoechoic nodule with microcalcifications. B. Solid hypoechoic nodule with multiple microcalcifications and macrocalcifications. C. 
Solid hypoechoic nodule with non-parallel orientation. D. Solid hypoechoic nodule with spiculated/microlobulated margin. Diagnosis: papillary 
carcinoma (A-D).
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reliable, and effective method for the diagnosis of the 
thyroid malignancies. The decision to perform FNA needs 
to be based on the malignancy and prognostic risks of 
a thyroid nodule. In the cases with poor prognostic risk 
factors including suspected cervical LN metastases, ETE, 
and confirmed distant metastases of thyroid cancer, FNA of 
the thyroid nodules should be performed regardless of the 
nodule size. In the patients without the abovementioned 
poor prognostic factors, we recommend that FNA of the 
thyroid nodules be performed on the basis of the cancer 
probability estimated by US and the nodule size (Table 2). 
Although whether the nodule size could be a predictor for 
malignancy is controversial (13-15), the primary tumor size 
of the thyroid cancer is closely related to the prognosis, and 
the cancer-specific mortality rate and the rate of recurrence 
is proportional to the size of the thyroid tumor (108, 109). 
If the nodule has a high or intermediate risk of malignancy 
(K-TIRADS 5 or 4), FNA is routinely recommended when 
the nodule size is ≥ 1 cm; if the nodule has a low risk of 
malignancy (K-TIRADS 3), FNA is recommended when the 
nodule size is ≥ 1.5 cm, in order to reduce unnecessary 
FNA procedures. If the nodule is in the benign condition 
(K-TIRADS 2), diagnostic FNA may be selectively considered 
for a spongiform nodule when the nodule size is ≥ 2 cm. 
Additionally, FNA may be performed for the therapeutic 
drainage of the cystic content as well as for diagnosis 
prior to ablation therapy in a pure cyst or a partially cystic 
nodule with comet-tail artifacts. With the FNA criteria of 
K-TIRADS categories 4 or 5 for nodules ≥ 1 cm and K-TIRADS 
3 for nodules ≥ 1.5 cm, the sensitivity, specificity, positive 
predictive value, negative predictive value, and accuracy 
for overall malignancy were 94.5%, 26.8%, 27.5%, 94.3%, 
and 42.2%, respectively according to a recent study where 
85.5% of the malignant tumors were PTC (25).
Although it is undetermined whether the known clinical 
risk factors for thyroid cancer including worrisome symptom, 
A
C
B
D
Fig. 3. Korean Thyroid Imaging Reporting and Data System 4 (intermediate suspicion). 
A. Solid hypoechoic nodule without suspicious US features. Diagnosis: benign follicular nodule. B. Solid isoechoic (predominantly isoechoic) 
nodule with microcalcification. Diagnosis: benign follicular nodule. C. Predominantly solid hypoechoic nodule with multiple microcalcifications. 
Diagnosis: papillary carcinoma. D. Predominantly cystic hypoechoic nodule with microcalcification (arrow). Diagnosis: papillary carcinoma. US = 
ultrasonography
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history of childhood radiation therapy, familial thyroid 
cancer, increased level of calcitonin, and incidentalomas 
with 18F-fluorodeoxyglucose uptake incrementally increase 
the malignancy risk estimated by a US pattern, FNA 
may be considered at lower size cutoffs of nodules with 
intermediate or low suspicion pattern in the clinical risk 
group. The current K-TIRADS categories are based on the 
US features of the nodules, irrespective of the clinical 
background. Although the US features of some nodules 
might correspond to the K-TIRADS categories 4 or 5, FNA 
may be avoided when they have serially correlated images 
or a typical clinical history such as degenerating nodule, 
post-ablation state, and subacute thyroiditis (110-112).
The decision to perform FNA is controversial in the 
cases with low-risk subcentimeter nodules without poor 
prognostic factors such as ETE and nodal or distant 
metastasis. For this category of nodules, we recommend 
that FNA can be selectively considered only for those 
nodules larger than 5 mm in size, with a high suspicion 
US pattern (K-TIRADS 5). The decision for the FNA of the 
subcentimeter nodules depends on the management strategy 
of the thyroid microcarcinomas. Active surveillance instead 
of immediate surgery could be considered in adult patients 
(> 18 years) with low-risk papillary thyroid microcarcinomas 
(113-118). Among the patients with the subcentimeter 
nodules, FNA of the nodules should be performed for the 
patients with risk factors requiring immediate surgery, 
who have poor prognostic factors such as ETE and nodal 
or distant metastasis, subcapsular nodules with possible 
tumor invasion of the trachea or the recurrent laryngeal 
nerve, or evidence of tumor progression (≥ 3 mm) upon 
serial examination (114, 117, 118). Immediate FNA may 
be deferred for the older patients (> 60 years) without risk 
factors requiring immediate surgery, considering the very 
low risk of disease progression and the relatively shorter 
follow-up periods in these patients (118); FNA may also be 
A
C
B
D
Fig. 4. Korean Thyroid Imaging Reporting and Data System 3 (low suspicion). 
None of nodules have any suspicious US features such as microcalcification, non-parallel orientation, and spiculated/microlobulated margins. A. 
Solid isoechoic nodule. Diagnosis: follicular variant papillary carcinoma. B. Predominantly solid and isoechoic nodule. Diagnosis: benign follicular 
nodule. C. Predominantly solid and hypoechoic nodule. Diagnosis: benign follicular nodule. D. Predominantly cystic and isoechoic nodule. 
Diagnosis: benign follicular nodule. US = ultrasonography
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deferred for patients who have a high surgical risk because 
of co-morbid conditions and a relatively short life. 
Although it is controversial, FNA may be selectively 
performed for the subcentimeter nodules (> 5 mm) with 
high suspicion US pattern by shared decision making in 
the young or middle-aged adult patients who are not 
candidates for immediate surgery. A recent American 
Thyroid Association guideline (20) discourages the FNA of 
asymptomatic subcentimeter thyroid nodules even when 
the nodules are highly suspicious for malignancy on the 
US images, in order to avoid an immediate admittance for 
surgical treatment because of a definite diagnosis of thyroid 
cancer; the guideline recommends FNA only when there 
is evidence of the disease progression in these patients 
(118). However, we can avoid unnecessary long-term active 
surveillance of some of the patients with benign nodules 
showing high suspicion US pattern (approximately 20–40% 
of nodules with high suspicion pattern); moreover, the 
FNA findings of the high-grade malignancies may change 
the management strategy from that of active surveillance 
to surgery, although such cases are rare. The nodule size 
threshold of 5 mm for FNA has no reliable evidence, and it 
was not a predictor of the tumor progression of the low-risk 
thyroid microcarcinomas in an observational study (114). 
However, the PTCs larger than 5 mm might potentially 
exhibit aggressive behavior such as clinically apparent 
metastatic nodes (cN1) (119), distant metastases (120, 
121), and tumor recurrence (122), although these issues are 
controversial (123, 124). 
In the case of multiple thyroid nodules, we recommend 
the FNA of one or more nodules that meet the FNA 
criteria based on the malignancy risk and nodule size. 
When lobectomy is considered in a patient with bilateral 
nodules, and a malignant tumor is diagnosed only in one 
of the lobes, FNA may be preoperatively performed for the 
contralateral nodule on the basis of a clinical decision. 
A
C
B
D
Fig. 5. Korean Thyroid Imaging Reporting and Data System 2 (benign).
A. Spongiform nodule. Diagnosis: benign (FNA not performed). B. Spongiform nodule with tiny microcystic changes. Diagnosis: benign follicular 
nodule. C. Predominantly cystic nodule with multiple comet tail artifacts. Diagnosis: benign follicular nodule with colloid. D. Cyst with comet-tail 
artifact. Diagnosis: benign (colloid cyst, FNA not performed). FNA = fine-needle aspiration
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Management of Thyroid Nodules after FNA
The follow-up and post-FNA management strategies 
should be determined on the basis of the US and clinical 
features, as well as the FNA results. The combined use of 
the US-based risk stratification and the Bethesda system 
could make possible a more timely detection of thyroid 
cancer, and might be useful for arriving at an optimal 
management decision after FNA in thyroid nodules (Table 3) 
(125-128). 
 
Non-Diagnostic or Unsatisfactory Cytology
The estimated malignancy rate of the nodules with 
nondiagnostic FNA results is 1–4% (125). In a recent meta-
analysis (129), the malignancy rate was 2.7% of all nodules 
with nondiagnostic FNA results and 16.8% of surgically 
resected nodules. Since the malignancy rate of the nodules 
with nondiagnostic FNA results is low, but not negligible, 
FNA should be repeated with US guidance for the nodules 
of this category (20, 92, 125). Thyroid nodules with high 
suspicion US pattern should be followed-up with US-FNA 
within 3–6 months of the initial treatment, and those with 
intermediate or low suspicion US pattern may be followed-
up with US-FNA within 6–12 months, depending on the 
nodule size and clinical features. The waiting period of 3 
month for the repeat FNA might be unnecessary, depending 
on the patient’s risk evaluation or the clinician’s preference 
(130, 131). Core needle biopsy (CNB) can be performed 
by an experienced operator in order to achieve a higher 
diagnostic adequacy with regard to the nodules with initial 
or repeated nondiagnostic cytological results (92, 132-135). 
 
Benign Cytology
When the cytological results indicate benign tumors, 
the follow-up strategy should be determined by risk 
stratification based on the US features (135-143). The 
estimated malignancy rate of the nodules with benign 
cytological results is 3.7%, according to the findings of a 
meta-analysis based on surgical diagnosis (129), and 1–2% 
based on the repeat FNA results or a long-term follow-up 
(127, 144, 145). Whether the false negative rates of FNA 
are higher (12, 146-148) or similar (13, 15, 149-151) in 
the large nodules is a matter of controversy. However, the 
false negative rates of the initial benign findings of FNA 
are quite different, and are relatively high (11.3–56.6%) 
for thyroid nodules with suspicious US features (127, 136-
142). Therefore, thyroid nodules with high suspicion US 
pattern should undergo repeat FNA within 6–12 months 
after the initial FNA. Thyroid nodules with intermediate 
or low suspicion US pattern are indicated for a follow-up 
US evaluation 1–2 years after FNA, and may be followed-
up every 2–4 years, thereafter (152). When a nodule with 
Table 3. Recommended Management Based on FNA Results and US Patterns in Thyroid Nodules
FNA Diagnosis US Patterns (K-TIRADS) Management 
Nondiagnostic High suspicion Repeat FNA or CNB* within 3–6 months†
Intermediate or low suspicion Repeat FNA or CNB* within 6–12 months†
Benign High suspicion Repeat FNA within 6–12 months
Intermediate or low suspicion US follow-up at 12–24 months
AUS/FLUS High suspicion Repeat FNA within 3–6 months
Intermediate or low suspicion Repeat FNA within 6–12 months‡
FN/SFN All nodules Diagnostic surgery (lobectomy)§
Suspicious malignancy High or intermediate suspicion Surgery 
Low suspicion Repeat FNA or surgery
Active surveillanceǁ
Malignant All nodules Surgery 
Active surveillanceǁ
*CNB may be considered instead of repeat FNA if experienced operator is available, †Optimal timing of repeat FNA or CNB should be 
determined by clinical decision based on consideration of nodule size, presence of poor prognostic factors such as suspected nodal 
metastasis or gross extrathyroidal extension, and clinical factors as well as US features, ‡Close follow-up may be considered depending on 
clinical risk factors, US features, patient preference, and, when possible, results of molecular studies. If repeat FNA cytology findings are 
inconclusive, close follow-up or diagnostic surgery can be considered, §Close follow-up instead of immediate surgery may be considered in 
some selected patients based on consideration of clinical factors, nodule size, US features, and, when possible, results of molecular study, 
ǁActive surveillance with close follow-up instead of immediate surgery may be considered in adult patients with probable or proven 
low-risk papillary microcarcinoma. AUS = atypia undetermined significance, CNB = core needle biopsy, FLUS = follicular lesions of 
undetermined significance, FN = follicular neoplasm, FNA = fine-needle aspiration, K-TIRADS = Korean Thyroid Imaging Reporting and 
Data System, SFN = suspicious for a follicular neoplasm, US = ultrasonography
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a benign FNA result is found to have increased in size at 
the follow-up, repeat FNA is not routinely recommended; 
it is, however, selectively performed depending on the 
malignancy risk estimated on the basis of the US findings, 
because of the low malignancy risk of these growing nodule 
(153). 
 
AUS/FLUS Cytology
The risk of malignancy for thyroid nodules with 
cytological results indicating atypia/follicular lesions of 
undetermined significance (AUS/FLUS) is estimated to be 
5–15% (125). The reported malignancy rates of the AUS/
FLUS nodules are variable; they were estimated to be 15.9% 
by a meta-analysis study (129), and might have a range 
of 26.6–37.8% (154). Although this diagnostic category 
has been recommended for a limited use of less than 7% 
(125), the AUS/FLUS are diagnosed in 0.8–27.2% of all of 
the thyroid FNA samples (129). For the nodules diagnosed 
as the AUS/FLUS, a repeat FNA is recommended, which 
results in a more definitive interpretation and might avoid 
diagnostic surgery in many cases (129, 155). The risk for 
malignancy for the AUS/FLUS nodules with suspicious US 
features is much higher, and is reported to be as high as 
60–80% (128, 156-159). Therefore, we recommend that 
FNA be repeated within 3–6 months for thyroid nodules 
with high suspicion US pattern, and within 6–12 months 
for those with indeterminate or low suspicion US pattern, 
instead of immediate surgery or surveillance. If the repeat 
FNA cytology findings are inconclusive, a close follow-up or 
diagnostic surgery can be decided upon. The utility of the 
repeat FNA is controversial because of its high rates (up to 
67%) of repeatedly inconclusive results (156, 160-162) and 
high false negative rates of benign diagnosis (163, 164). 
The malignancy risk of the AUS/FLUS category of nodules 
might vary according to their subcategory; the AUS/
FLUS subcategory presenting nuclear atypia has a higher 
malignancy risk than those presenting architectural or other 
atypia (154, 161, 165). Although further investigations are 
necessary, the management strategy based on the subtype 
and US features of the nodules might be helpful for arriving 
at an optimal management decision (128). The CNB method 
might be more useful for obtaining more conclusive results 
for the AUS/FLUS nodules than repeat FNA (134, 166-169). 
Molecular testing is currently not recommended for routine 
use; however, their use may be considered in selected 
cases, in order to supplement the findings of malignancy 
risk assessment (170, 171). 
Follicular Neoplasm or Suspicious for a Follicular 
Neoplasm Cytology
Diagnostic surgery is generally recommended for the 
nodules with follicular neoplasm or suspicious for a 
follicular neoplasm (FN/SFN) cytological results (20, 92, 95, 
125). However, close follow-up can be considered instead of 
immediate surgery upon considering the clinical risk factors, 
US features, and results of the molecular study. The US 
features of the follicular adenomas and carcinomas overlap 
substantially, and there is insufficient data regarding 
the malignancy risk stratification of the nodules of this 
category, based on the US features. A recent study (153) 
suggests that if a FNA-diagnosed FN/SFN nodule is found to 
be growing at the follow-up, its malignancy risk is higher 
compared to that of the FN/SFN nodules that have been 
treated by immediate surgery. 
 
Suspicious for Malignancy
Surgical treatment is recommended for the nodules with 
suspicious malignant cytological results (20, 92, 95, 125). 
If a nodule has a low suspicion or benign US pattern, repeat 
FNA may be considered before surgery, given the possibility 
of false positive results in the nodules without suspicious 
US features (172). 
 
Malignancy
Surgical treatment is recommended for the nodules with 
malignant cytological results. However, surgery should be 
carefully determined on an individual basis for each patient 
according to the risk-benefit ratio. Active surveillance 
by means of close follow-ups can be considered as an 
alternative to immediate surgery in adult patients with low-
risk thyroid microcarcinomas without aggressive features 
or high-grade malignant tumors (113, 114, 117, 118). 
Close follow-up may also be preferred instead of immediate 
surgery considering the risk-benefit ratio of surgery in the 
cases where the patient has a high surgical risk because of 
co-morbid conditions, relatively short life, or concurrent 
medical or surgical issues. 
 
US and CT Diagnosis of Cervical Lymph Node 
Metastasis
The frequency of metastasis to the cervical LNs in PTC has 
been estimated to be as high as 60–70% (173, 174), and 
the presence of the LN metastases is known to be highly 
correlated with the loco-regional recurrence rather than the 
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disease-specific mortality (175, 176). US is the established 
primary imaging modality for the assessment of the LNs 
in the patients with thyroid nodules and proven thyroid 
cancers. Contrast-enhanced CT has not been routinely 
applied for the preoperative evaluation of thyroid cancer, 
and the use of iodine-based contrast media was strictly 
restricted before surgery because of the concerns over 
the disturbed radioactive iodine uptake for months and 
the delay of radioiodine treatment (177, 178). However, 
recent studies have demonstrated that the delaying of the 
Table 4. Imaging-Based Risk Stratification of Cervical Lymph Nodes for Nodal Metastasis
Category US CT 
Suspicious*
Cystic change Cystic change 
Calcification (micro/macro) Calcification (micro/macro) 
Hyperechogenicity (focal or diffuse) Heterogeneous enhancement 
Abnormal vascularity (peripheral or diffuse) Strong enhancement (focal or diffuse) 
Indeterminate†
Loss of central hilar echo and absence of central 
  hilar vascularity
Loss of central hilar fat and absence of central 
  hilar vessel enhancement
Benign‡
Central hilar echo
Central hilar vascularity 
Central hilar fat
Central hilar vessel enhancement 
*Lymph nodes with any imaging feature for suspicious lymph nodes are included for this category regardless of presence of any imaging 
feature for benign or indeterminate lymph nodes, †Lymph nodes not included in suspicious or benign categories, ‡Lymph nodes with 
any imaging feature of either central hilar fat or central hilar vessels are considered as benign category if there is no imaging feature of 
suspicious lymph nodes. US = ultrasonography
A
D
C
B
E
Fig. 6. Suspicious lymph nodes (ultrasonography features). 
A. Large cystic nodal mass. B. Small focal cystic change and hyperechogenicity in lymph node. C. Hyperechogenicity and macrocalcifications 
in lymph node. D. Multifocal hyperechogenicity (black arrows) and microcalcification (white arrow) in lymph node. E. Hyperechogenicity, 
microcalcification, and abnormal hypervascularity in lymph node. Diagnosis: metastatic papillary carcinoma (A-E).
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radioiodine therapy is not necessary in the patients who have 
undergone preoperative contrast-enhanced CT, and that 
the body iodine content is not an important determinant 
of thyroid ablation (179-183). Contrast-enhanced CT has a 
complementary role in the preoperative assessment of the 
extent of the primary tumors and nodal metastases (184-
188). We recommend preoperative contrast-enhanced CT 
for the patients with a suspected invasive primary tumor 
or cervical LN metastasis. Although the added value of the 
routine preoperative use of the neck CT for the detection of 
the LN metastases has been reported in the patients with 
PTC (184, 186), there is insufficient data and it remains 
controversial (189). 
 
US and CT Classification of the Cervical Lymph Nodes 
According to the Risk of Nodal Metastasis
Based on the US and CT features, cervical LNs can be 
classified into three categories–suspicious, indeterminate, 
benign–based on the risk of the LN metastasis (190) 
(Table 4, Figs. 6-9). The US criteria for suspicious LNs 
have been reported to be highly specific and predictive of 
LN metastases (approximately 80–90%) in node-by-node 
correlation studies (191, 192). The CT criteria for suspicious 
LNs have been also reported to have high specificity 
(70–90%) and positive predictive value (70–80%) for LN 
metastases in level-by-level studies (184, 185). Benign LNs 
are defined as the LNs which do not have imaging features 
of suspicious LNs and show any typical imaging feature 
of benign nodes including US feature of either a central 
echogenic hilum or a central radiating hilar vascularity and 
CT feature of either a central hilar fat or a central hilar 
vessel enhancement. Indeterminate LNs are defined as the 
LNs which have no imaging feature of suspicious or benign 
LNs. Indeterminate LNs include the LNs with an eccentric or 
deformed configuration of the hilum or hilar vessels as well 
as the LNs with loss of both central hilar fat and central 
hilar vascularity on US or CT regardless of nodal shape (ovoid 
or round shape). These imaging features for indeterminate 
A
D
B
E
C
F
Fig. 7. Suspicious lymph nodes (CT features).
A. Large nonenhancing cystic nodal mass. B. Small focal cystic change and strong enhancement in lymph node. C. Diffuse, strong enhancement 
in lymph node. D. Heterogeneous mild enhancement in lymph node (arrow). E, F. Multiple variable-sized nodal calcifications and tiny nodal 
calcification (F, arrow) on unenhanced CT image. Diagnosis: metastatic papillary carcinoma (A-F).
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LNs are not specific for the metastatic nodes (190, 192). 
However, it is likely that these criteria for indeterminate 
LNs could be helpful to distinguish the malignant LNs 
from the benign if they can be applied along with the size 
criteria, which should be verified in future studies (192). 
Ultrasonography has been regarded as an insufficient 
imaging modality because of its relatively low sensitivity 
for the detection of the metastatic LNs, especially in the 
central compartment (173, 193-195). The low sensitivity 
may be explained by the presence of the overlying thyroid 
gland in the central neck and that of nodal micrometastases 
(less than 2 mm in diameter), which are mostly undetected 
by US. The macroscopic metastatic nodes present a high 
risk of postoperative recurrence; however, the microscopic 
metastatic nodes have no significant association with the 
risk of recurrence, and the recurrence rate is similar to 
that of the pathologically negative nodes (176, 196-200). 
Therefore, while the preoperatively identified macroscopic 
metastatic LNs have a nodal prognostic significance and 
are regarded as clinically apparent nodes (cN1), most of the 
microscopic metastatic nodes undetected by imaging might 
have little clinical significance (176). 
 
FNA Indication for the Cervical Lymph Nodes 
The clinical role of US or CT in the preoperative evaluation 
of the cervical LNs is to detect the clinically apparent 
and macroscopic metastatic LNs, which are the targets of 
surgical therapy. Therefore, accurate preoperative imaging is 
crucial for the complete surgical removal of the macroscopic 
metastatic LNs in the patients with thyroid cancers. 
In contrast, an insufficient preoperative assessment of 
the cervical LNs would eventually lead to a recurrent or 
persistent disease in the neck. We recommend FNA for the 
treatment of the suspicious LNs with a short diameter > 3–5 
A
C
B
D
Fig. 8. Indeterminate lymph nodes.
A, B. US features of indeterminate lymph nodes. US images shows ovoid and elongated lymph nodes which show loss of central echogenic 
hilum and central hilar vascularity. Note absence of any suspicious US feature in these nodes. Diagnosis: probable benign lymph node (FNA not 
performed). C, D. CT features of indeterminate lymph nodes. CT images show lymph nodes that do not have central fat hilum and central hilar 
vessel enhancement. Note absence of any suspicious CT feature in these nodes. Diagnosis: probably benign lymph node (arrow) (C, FNA not 
performed), metastatic papillary carcinoma (arrow) (D). FNA = fine-needle aspiration, US = ultrasonography
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mm and the indeterminate LNs with a short diameter > 5 
mm in the preoperative patients with suspected or proven 
thyroid cancer (Table 5). 
Recent studies reported that the postoperative suspicious 
lesions in the thyroid bed or lateral necks usually remain 
stable, and have a low potential for structural disease 
progression (201, 202). In these studies, surgical resection 
at the time of structural disease progression was successful 
without evidence of local invasion or distant metastases. 
These data suggest that appropriately selected patients can 
be offered a strategy for close monitoring with serial serum 
thyroglobulin (Tg) measurements and the US evaluation 
of the suspicious lesions. The decision to perform US-
guided FNA for the treatment of cervical LNs should be 
made based on whether the results of the biopsy will lead 
to an appropriate and reasonable therapeutic intervention. 
Therefore, considering the low efficacy of the reoperation 
and the less aggressive nature of the recurred nodes, the 
suspicious or indeterminate LNs > 8–10 mm at the short 
axial diameter could be a reasonable indication for US-
guided FNA in the postoperative evaluation of the cervical 
LNs (Table 5). However, when the LN is close to the vital 
organ or the non-surgical treatment including image-guided 
ablation (ethanol or radiofrequency) are taken into account, 
FNA could be performed even for the smaller LNs.
US-Based Minimally Invasive Nonsurgical 
Ablation Therapy 
Minimally invasive treatments are indicated in thyroid 
nodules with clinical problems such as obvious symptoms, 
cosmetic concerns, and hyperfunction (203). Chemical 
(ethanol) or thermal (laser and radiofrequency) ablation 
modalities can be considered for the improvement of 
A
C
B
D
Fig. 9. Benign lymph nodes. 
A, B. US features of benign lymph nodes. US image shows elongated lymph node with prominent central echogenic hilum and central hilar 
vascularity (A). US image shows ovoid lymph node with small deformed echogenic hilum (arrow), however, color-Doppler US shows prominent 
typical central hilar vascularity (B). C, D. CT features of benign lymph nodes. CT image shows lymph node with central hilar fat (C, arrows) and 
enhanced lymph node with central hilar vessel enhancement (D, arrow). Diagnosis: benign lymph node (A-D, FNA not performed). FNA = fine-
needle aspiration, US = ultrasonography
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the clinical problems by reducing the volume of benign 
thyroid nodules (10). The recommendations for the 
minimally invasive treatment of benign thyroid nodules are 
summarized in Table 6. 
In cystic thyroid nodules (cystic portions > 90%) with 
symptomatic cosmetic problems, simple aspiration is 
the first-line management tool for both diagnostic and 
therapeutic purposes. However, the recurrence rate is 
as high as 80% after simple aspiration, depending on 
the number and volume of the aspirated cysts (204). 
Ethanol ablation can be considered for the treatment of 
the recurrent cystic thyroid nodules on the basis of the 
compressive symptoms and cosmetic concerns. Ethanol 
ablation has a therapeutic efficacy comparable to that of 
radiofrequency ablation, but is less expensive than the 
latter; it should be considered as the first-line treatment 
modality for cystic thyroid nodules (205-206). 
Thermal ablation shows high efficacy and safety in 
the treatment of the benign solid thyroid nodules, and 
may be considered as a valid alternative to surgery (207-
211). Recent systematic reviews and meta-analyses have 
demonstrated that both radiofrequency and laser ablation 
achieved a significant volume reduction in the benign solid 
thyroid nodules; however, radiofrequency ablation was 
revealed as having efficacy superior to that of laser ablation 
for volume reduction. The studies also showed that both the 
intervention modalities are devoid of major complications 
(212). Because of potential complications, thermal ablation 
procedures should be performed only by experienced 
operators.
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